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ABSTRACT
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by 
acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the 
immunological characteristics have not been fully elucidated in patients with HPD. We 
prospectively recruited patients with metastatic non-small cell lung cancer treated with 
anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood 
before treatment and 7-days post-treatment. HPD was defined as ≥2-fold increase in both 
tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. 
Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to 
phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced 
durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 
experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly 
lower progression-free survival (p<0.001) and overall survival (p<0.001). When peripheral 
blood immune cells were examined, the pre-treatment frequency of CD39+ cells among CD8+ 
T cells was significantly higher in patients with HPD compared to those with NHPD, although 
it showed borderline significance to predict HPD. Other parameters regarding regulatory 
T cells or myeloid derived suppressor cells did not significantly differ among patient 
groups. Our findings suggest high pre-treatment frequency of CD39+CD8+ T cells might be 
a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our 
results and better delineate the immune landscape of HPD.
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INTRODUCTION
Immune checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 monoclonal Abs, have 
changed treatment paradigm in broad ranges of solid tumors due to the high and durable 
response (1). Despite such efficacy, most patients treated with ICIs suffer from progression, 
and even hyperprogression. Hyperprogressive disease (HPD) is characterized by a paradoxical 
acceleration of tumor growth after treatment with ICIs. Although questions have been raised 
as to whether HPD is a unique entity in response to ICIs, it is now well-established as a 
distinct type of progression in multiple types of cancer (2). However, the pathogenesis of this 
phenomenon has not been fully elucidated.
Recently, a role of tumor-associated macrophages or regulatory T cells (Tregs) has been 
suggested in the pathogenesis of HPD (3,4). In addition, PD-1 expression on cancer cells has 
been suggested to promote HPD (5). However, most of the mechanistic studies have been 
limited to mouse tumor models, which represent general tumor progression rather than 
HPD. Given the lack of HPD-specific mouse models, more human-based investigations are 
needed. A number of clinical factors, such as older age, higher number of metastatic lesions, 
locoregional disease recurrence, and specific genomic alterations, have been proposed to be 
associated with HPD (6-8). However, limited data exist on the immune responses associated 
with HPD.
In the present study, we aimed to uncover the immunological characteristics specific to 
HPD using peripheral blood obtained before and early after anti-PD-1/PD-L1 treatment in 
patients with non-small cell lung cancer (NSCLC). We mainly focused on CD8+ and CD4+ T 
cells, which are the main targets of anti-PD-1/PD-L1 therapy, and suppressive immune cells 
commonly detected in peripheral blood, such as Tregs and myeloid derived suppressor cells 
(MDSCs). The pre-treatment and post-treatment measures of and fold change in immune cell 
parameters were analyzed to evaluate the correlation with HPD.
MATERIALS AND METHODS
Study cohort
Patients with histologically confirmed metastatic NSCLC treated with anti-PD-1/PD-L1 
monotherapy between April 2015 and April 2019 were included in this study (n=115). 
Peripheral blood was collected before treatment and 7 days after treatment initiation. Among 
the 115 patients, 82 had both pre-treatment and post-treatment blood available, whereas 52 
patients had only pre-treatment blood available. Peripheral blood mononuclear cells (PBMCs) 
were isolated from peripheral blood by density gradient centrifugation. This study was 
approved by the Institutional Review Board of Samsung Medical Center. All patients provided 
informed consent prior to inclusion in the study.
Treatment response evaluation
Tumor response was assessed by computer tomography or magnetic resonance imaging 
every 8–9 weeks according to the RECIST 1.1 criteria. Tumor growth kinetics (TGK) were 
defined as the change in the sum of the longest diameter (SLD) of target lesions per month 
(9). The TGK ratio (TGKR) was defined as the ratio of post-treatment TGK (TGKPOST) and pre-
treatment TGK (TGKPRE). Tumor growth rate (TGR) was defined as the estimated increase in 
tumor volume per month (10). Briefly, TGR is derived from the assumption that an increase 
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in tumor volume follows an exponential law in which the tumor volume is approximated from 
the SLD of target lesions. The TGR ratio (TGRR) was defined as the ratio of post-treatment 
TGR (TGRPOST) and pre-treatment TGR (TGRPRE). HPD was defined as patients with both 
TGKR and TGRR ≥2. Durable clinical benefit (DCB) was defined as a complete response (CR), 
partial response (PR), or stable disease (SD) lasting longer than 6 months. Patients not 
classified as either HPD or DCB were classified as non-hyperprogressive progression (NHPD).
Flow cytometry
Multi-color flow cytometry was performed using the PBMCs collected pre-treatment and 
post-treatment (11). MDSCs were analyzed on the same day as PBMC isolation because MDSCs 
are prone to cell death following freezing and thawing (12). A total of 102 fresh samples were 
analyzed for MDSCs. Other immune cell populations were analyzed using cryopreserved 
PBMCs. Anti-CD8 (SK1 and RPA-T8), anti-CD3 (HIT3a), anti-CD4 (SK3), anti-CD25 (M-A251), 
anti-CD45RA (HI100), anti-CD28 (CD28.2), anti-CD56 (NCAM16.2), anti-CD15 (HI98), 
anti-HLA-DR (G46-6), anti-IFN-γ (B27), anti-TNF-α (MAb11), and anti-IL17A (N49-653) were 
obtained from BD Biosciences; anti-PD-1 (EH.12.2H7), anti-CD127 (A019D5), anti-CD11b 
(ICRF44), anti-CD39 (A1), anti-CD73 (AD2), and anti-Ki-67 (Ki-67) from BioLegend; anti-FoxP3 
(PCH101), anti-CD14 (61D3), and anti-CD19 (HIB19) from eBioscience; and anti-human IgG4 
Fc (HP6025) from Southern Biotech. In post-treatment PBMCs, PD-1+ cells were detected by 
anti-human IgG4 staining due to the therapeutic binding of pembrolizumab or nivolumab 
(human IgG4) to cell surface PD-1. The LIVE/DEAD Fixable Red Dead Cell Stain Kit (Invitrogen) 
was used to gate dead cells. MDSCs were defined according to previous recommendations 
(13). Intracellular staining was performed using a FoxP3 transcription factor staining buffer set 
(eBioscience) and specific Abs. Intracellular cytokine staining was performed by stimulating 
PBMCs with an anti-CD3 Ab (1 μg/mL; OKT3, eBioscience) for 6 h. Brefeldin A (GolgiPlug, BD 
Biosciences) was added 1 h after anti-CD3 stimulation.
Statistical analysis
Continuous variables in patients with DCB, NHPD, and HPD were compared by one-
way ANOVA and post-hoc analysis was performed by Tukey's multiple comparisons test. 
Categorical variables were compared using the χ2 test or Fisher's exact test as indicated. 
Progression-free survival (PFS) was defined as the time from the start of anti-PD-1/PD-L1 
therapy to either disease progression (according to RECIST v1.1) or death from any cause. 
Receiver Operating Characteristics (ROC) curve was generated to evaluate the predictive 
value for HPD. Overall survival (OS) was defined as the time from the start of anti-PD-1/PD-
L1 therapy to death from any cause. Survival curves were estimated using the Kaplan–Meier 
method and comparisons made by the log-rank test. All statistical analyses were performed 
in Prism software version 7.0 (GraphPad) and IBM SPSS Statistics 25 (IBM Corp).
RESULTS
Patient characteristics
A total of 115 patients treated with anti-PD-1/PD-L1 monotherapy were analyzed. The 
characteristics of the cohort are shown in Table 1. None of the patients received prior ICI. 
Patients received median 1 line (range, 0–9 lines) of previous systemic treatment. Most 
patients received anti-PD-1 monotherapy while 10 patients (8.7%) received anti-PD-L1 
monotherapy. The best response after anti-PD-1/PD-L1 treatment was CR in 1 (0.9%), PR in 
34 (29.5%), SD in 37 (32.2%), and PD in 43 (37.4%) patients.
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Defining patients with HPD
To assess HPD, tumor growth dynamics before and after treatment with anti-PD-1/PD-L1 
were evaluated by estimating TGR and TGK in 43 patients who had PD as their best response 
(Fig. 1A and B). TGRR and TGKR were assessed to account for an acceleration in tumor growth 
following anti-PD-1/PD-L1 treatment. Despite the difference in definitions, TGRR and TGKR 
were tightly correlated (r=0.95; p<0.001; Fig. 1C). However, 4 patients only satisfied either 
TGRR or TGKR ≥2.0. HPD was defined as fulfilling both TGRR and TGKR ≥2.0 (Fig. 1C). 
Among the 115 patients, 52 (45.2%) achieved DCB, 19 experienced HPD (16.5%), and 44 
(38.3%) exhibited no durable benefit but did not fulfill the HPD criteria (NHPD). Patients 
with DCB had significantly better performance status and fewer previous lines of treatment 
compared to patients with NHPD or HPD, however we found no significant differences in 
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Table 1. Patient characteristics
Characteristics Total (n=115) DCB (n=52) NHPD (n= 44) HPD (n=19) p-value
Age, median (range) (yr) 62 (35–88) 66 (41–88) 61 (35–80) 62 (47–80) 0.047*
Sex 0.212
Male 93 (80.9) 45 (86.5) 32 (72.7%) 16 (84.2%)
Female 22 (19.1) 7 (13.5) 12 (27.3%) 3 (15.8%)
ECOG performance status 0.142
0–1 102 (88.7) 49 (94.2) 38 (86.4%) 15 (78.9%)
2 13 (11.3) 3 (5.8) 6 (13.6%) 4 (21.1%)
Histology 0.197
Adenocarcinoma 68 (59.1) 28 (53.8) 31 (70.5%) 9 (47.4%)
Squamous cell carcinoma 39 (33.9) 21 (40.4) 11 (25.0%) 7 (36.8%)
Others 8 (7.0) 3 (5.8) 2 (4.5%) 3 (15.8%)
Tumor burden (cm) 4.5 (0.5–15.7) 4.8 (0.5–12.2) 4.5 (1.0–15.7) 3.6 (1.5–12.9) 0.656
PD-L1 (%) 0.565
<1 17 (14.8) 5 (9.6) 9 (20.5) 3 (15.8)
≥1 and <50 20 (17.4) 9 (17.3) 8 (18.2) 3 (15.8)
≥50 63 (54.8) 33 (63.5) 21 (47.7) 9 (47.4)
Not performed 15 (13.0) 5 (9.6) 6 (13.6) 4 (21.1)
Number of previous treatment 1 (0–9) 1 (0–5) 2 (0–9) 2 (0–7) 0.049*
Anti-PD-1 agent 0.072
Atezolizumab/Avelumab 10 (8.7) 7 (13.5) 2 (4.6%) 1 (5.2%)
Nivolumab 42 (36.5) 12 (23.1) 21 (47.7%) 9 (47.4%)
Pembrolizumab 63 (54.8) 33 (63.5) 21 (47.7%) 9 (47.4%)
DCB, durable clinical benefit; NHPD, non-hyperprogressive progression; HPD, hyperprogression; ECOG, Eastern Cooperative Oncology Group.














































Figure 1. TGR and TGK in patients with progressive disease as the best response according to RECIST 1.1 criteria (n=43). (A) TGR before anti-PD-1/PD-L1 treatment 
(TGRPRE) and during treatment (TGRPOST). The dashed line indicates TGRPRE=TGRPOST. Red dots indicate TGR ratio (TGRR=TGRPOST/TGRPRE)≥2.0. Blue indicates 
1.0≤TGRR<2.0, and green indicates TGRR<1.0. (B) Percentage change in SLD before and during anti-PD-1/PD-L1 treatment. (C) Correlation between TGRR and TGKR. 
Patients fulfilling both TGRR≥2.0 and TGKR≥2.0 were defined as hyperprogressive disease. 
TGR, tumor growth rate; TGK, tumor growth kinetics; SLD, sum of the longest diameter.
baseline patient characteristics between patients with NHPD and HPD (Table 1). Regarding 
the anti-PD-1/PD-L1 agents administered, pembrolizumab was more commonly administered 
in patients with DCB than those with NHPD and HPD, but the distribution of the anti-PD-1/
PD-L1 agents were similar between patients with NHPD and HPD (Table 1).
At a median follow-up of 18.2 months (range, 4.2–54.3 months), median PFS of patients with 
DCB, NHPD, and HPD was 14.8 months (95% confidence interval [CI], 10.0–19.5 months), 
1.9 months (95% CI, 1.5–2.3 months), and 1.1 months (95% CI, 0.7–1.5 months), respectively 
(p<0.001; Fig. 2A). The median OS of patients with NHPD and HPD was 7.2 months (95% CI, 
4.6–9.7 months) and 3.4 months (95% CI, 2.7–4.2 months), respectively (p<0.001; Fig. 2B). 
For patients with DCB, OS was not reached.
Correlation between HPD and peripheral blood immune cells following anti-
PD-1/PD-L1 therapy
Next, we examined the peripheral blood immune cells pre-treatment and 1-week post-treatment 
using flow cytometry. The gating strategies are provided in Supplementary Fig. 1.  
The frequencies and phenotypes of CD8+ T cells, CD4+ T cells, and MDSCs were analyzed. 
T-cell markers related to exhaustion (PD-1, CD39, and CD73), differentiation status (CD28 
and CD45RA), proliferation (Ki-67), and cytokine secretion (IFN-γ, TNF-α, and IL-17A) 
were included. The frequency of MDSCs, including the subpopulations PMN-MDSCs (Lin- 
CD15+CD14−CD11b+HLA-DR−/lo) and M-MDSCs (Lin- CD14+CD15−HLA-DR−/lo), were evaluated. 
Tregs were also evaluated and analyzed according to the subsets naïve (Fraction I) Tregs, effector 
(Fraction II; FII) Tregs, and non-suppressive cells (Fraction III) (14). The pre-treatment and 
post-treatment measures of, and fold change in each parameter were correlated with treatment 
response to identify HPD-specific markers. The values of each examined parameter are 
summarized in Supplementary Table 1. Among the parameters evaluated, the pre-treatment 
frequency of CD39+ cells among CD8+ T cells and fold change in the frequency of Ki-67+ cells 
among PD-1+CD8+ T cells post-treatment exhibited significant differences among patients with 
DCB, NHPD, and HPD (Supplementary Table 1). The frequency of MDSCs, which was reported 
to predict treatment outcome after anti-PD-1 therapy (12), did not significantly differ among 
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Figure 2. PFS and OS among the patients in this study. (A) PFS and (B) OS in patients with DCB (n=52), NHPD (n=44), and HPD (n=19). 
PFS, progression-free survival; OS, overall survival; DCB, durable clinical benefit; NHPD, non-hyperprogressive progressive disease.
patients with DCB, NHPD, and HPD (Figure 3A-C). The fold change in the frequency of Ki-67+ 
cells among PD-1+CD8+ T cells post-treatment did not show significant differences between 
patients with NHPD and HPD, although patients with DCB exhibited significantly higher values 
(Fig. 3D). The pre-treatment frequency of CD39+ cells among CD8+ T cells was significantly 
higher in patients with HPD compared to those with NHPD (Fig. 3E). There was a trend of higher 
pre-treatment frequency of CD39+ cells among CD8+ T cells in patients with HPD compared 
to those with DCB although it was not statistically significant. The pre-treatment frequency of 
CD39+ cells among CD8+ T cells showed borderline significance to predict HPD (area under the 
curve 0.66, p=0.066; Fig. 3F). Interestingly, PD-1+TIGIT+ cells, which have been shown to be 
more susceptible to activation-induced cell death following PD-1 blockade (15), were enriched in 
CD39+CD8+ T cells compared to CD39−CD8+ T cells (Supplementary Fig. 2).
Regulatory T cells in patients with HPD
A role of FII Tregs in the pathogenesis of HPD was recently reported (4). When we evaluated 
the change in frequency and proliferation of peripheral blood Tregs after anti-PD-1/PD-
L1 monotherapy, we observed an increase in proliferating Ki-67+ FII Tregs, but it was not 
statistically significant between NHPD and HPD patients (Fig. 4A). No significant differences 
were observed in the fold change in Ki-67+ FII Tregs following anti-PD-1/PD-L1 treatment 
among patients with DCB, NHPD, and HPD (Fig. 4B). We also evaluated the proliferative 
response in PD-1+ FII Tregs, but no significant difference among patients with DCB, NHPD, 
and HPD was noted (Fig. 4C). Moreover, we found no significant differences in the fold 
change in the frequency of FII Tregs or PD-1+ FII Tregs (Fig. 4D).
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Figure 3. Immune cell parameters that significantly differ among patients with DCB, NHPD, and HPD. (A) Frequency of pre-treatment PMN-MDSCs (Lin−CD14−
CD15+CD11b+HLA−DR−/lo) among live single cells. (B) Frequency of pre-treatment M-MDSCs (Lin−CD14+HLA−DR−/lo) among live single cells. (C) Frequency of pre-
treatment MDSCs (frequency of M-MDSCs and PMN-MDSCs) among live single cells. (D) Fold change in the frequency of Ki-67+ cells among PD-1+CD8+ T cells after 
anti-PD-1/PD-L1 therapy. (E) Frequency of pre-treatment CD39+ cells among CD8+ T cells. (F) The receiver operating characteristics curve for prediction of HPD 
with the frequency of pre-treatment CD39+ cells among CD8+ T cells. 
n.s., not significant; DCB, durable clinical benefit; NHPD, non-hyperprogressive progressive disease; HPD, Hyperprogressive disease; MDSC, myeloid derived 
suppressor cell; AUC, area under the receiver operating characteristics curve. 
*p<0.05, **p<0.01.
CD28+PD-1+CD8+ T cells in patients with HPD
Our group recently reported that tumor-infiltrating CD28+PD-1+CD8+ T cells, which express 
TCF1 and retain stemness, are the population responding to PD-1 blockade (16). Based on these 
results, we measured the frequency of CD28+ cells among peripheral blood PD-1+CD8+ T cells and 
found a decreasing trend from DCB patients to HPD patients regarding the baseline frequency of 
CD28+ cells among PD-1+CD8+ T cells, but the difference was not significant (Fig. 4E).
DISCUSSION
In the present study we aimed to evaluate the immunological characteristics specific for HPD 
that are distinct from non-hyperprogressive progression using peripheral blood obtained 
before and after treatment. Compared to previous studies that defined HPD with either 
TGKR or TGRR only (9,10,17), we more stringently defined HPD as fulfilling both TGKR and 
TGRR≥2. For immune cell analysis, we mainly focused on CD8+ and CD4+ T cells, which are 
the main effectors and target cells of anti-PD-1/PD-L1 therapy, and other suppressive cell 
populations that have been shown to correlate with a poorer response to PD-1 blockade, such 
as MDSCs and Tregs (4,18,19). We observed a significant difference in PFS and OS between 
NHPD and HPD patients, implying a distinct clinical course of HPD, and found that the pre-
treatment frequency of CD39+ cells among CD8+ T cells was significantly higher in patients 
with HPD compared to patients with NHPD.
CD39 is an ectonucleotidase expressed on the cell surface and CD39 expression has been 
reported to identify terminally exhausted CD8+ T cells (20,21). Severely or terminally 
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Figure 4. Regulatory and CD28+PD-1+CD8+ T cells in patients with DCB, NHPD, and HPD. (A) Frequency of Ki-67+ cells among FII Tregs (FoxP3hiCD45RA−) pre- and 
post-treatment. (B) Fold change in the frequency of Ki-67+ cells among FII Tregs following anti-PD-1/PD-L1 treatment. (C) Fold change in the frequency of Ki-67+ 
cells among PD-1+ FII Tregs following anti-PD-1/PD-L1 treatment. (D) Fold change in the frequency of FII Treg and PD-1+ FII Tregs among CD4+ T cells following anti-
PD-1/PD-L1 treatment. (E) Frequency of CD28+ cells among PD-1+CD8+ T cells before treatment. 
DCB, durable clinical benefit; NHPD, non-hyperprogressive progressive disease; HPD, Hyperprogressive disease; n.s., not significant. 
***p<0.001.
exhausted CD8+ T cells have been demonstrated as a subpopulation that does not respond 
to PD-1 blockade (22). Although not specific to HPD, our group recently demonstrated that 
the frequency of CD39+ cells among CD8+ T cells in peripheral blood predicts the efficacy 
of anti-PD-1 therapy in patients with NSCLC (12). It can be hypothesized that an increase 
in terminally exhausted CD39+CD8+ T cells may lead to a lack of response to PD-1 blockade, 
resulting in HPD. However, HPD, where the growth rate of tumor cells increase after 
treatment, is a distinct process from lack of treatment response (2). Although the underlying 
mechanisms of HPD is not fully understood, some hypotheses regarding the association 
of CD39+CD8+ T cells and HPD may be suggested. A recent report showed that higher 
frequency of severely exhausted PD-1+TIGIT+CD8+ T cells in peripheral blood at baseline can 
predict HPD in NSCLC patients, and demonstrated that these cells were more vulnerable to 
activation-induced cell death following T-cell receptor stimulation with PD-1 blockade (15). 
We found that the frequency of PD-1+TIGIT+ cells were significantly higher in CD39+CD8+ T 
cells compared to CD39−CD8+ T cells. Therefore, CD39+CD8+ T cells may also be vulnerable 
to activation-induced cell death following PD-1 blockade and may result in a loss of tumor-
specific T cells resulting in a paradoxical tumor progression. Another study demonstrated 
the immunosuppressive role of CD39+CD8+ T cells via the ectonucleotidase activity of CD39 
(21). Therefore, anti-PD-1-induced proliferation of CD39+CD8+ T cells may lead to further 
suppression of anti-tumor immune responses through increased ATP hydrolysis and 
adenosine. However, we measured the frequency of CD39+CD8+ T cells in the peripheral 
blood which may not accurately reflect the composition of CD39+ cells among CD8+ T cells 
in the tumor microenvironment. Further studies utilizing pre-treatment tissue biopsies may 
further elucidate the importance of this terminally exhausted CD8+ T cell subpopulation in 
the development of HPD.
The magnitude of CD8+ T-cell reinvigoration measured by the increase in proliferating 
PD-1+CD8+ T cells has been demonstrated to predict the response to anti-PD-1 therapy in 
multiple types of cancers, including melanoma and NSCLC (23,24). In this study, we found a 
significantly higher fold change in the frequency of Ki-67+ cells among PD-1+CD8+ T cells after 
anti-PD-1/PD-L1 treatment in patients with DCB compared to patients with NHPD or HPD, 
which is consistent with previous results. However, the fold change was not significantly 
different between patients with HPD and NHPD. We also detected a significantly lower 
baseline frequency of MDSCs in patients with DCB, which is in line with a recent study by 
Ko et al. (12). However, the frequency of MDSCs at baseline were similar between NHPD and 
HPD patients. These data imply that the response of PD-1+CD8+ T cells and baseline frequency 
of MDSCs, which predict treatment response after anti-PD-1, do not specifically predict HPD. 
Moreover, these findings indicate that PD-1+CD8+ T cells and MDSCs may not be involved in 
the process of HPD.
We also evaluated the frequency of CD28+ cells among PD-1+CD8+ T cells. Recently, our group 
identified that tumor-infiltrating CD28+PD-1+CD8+ T cells highly express TCF1 and respond to 
PD-1 blockade, whereas CD28−PD-1+CD8+ T cells are terminally exhausted and poorly respond 
to PD-1 blockade (16). TCF1, a Wnt family transcription factor, has been demonstrated to be 
a key marker of anti-PD-1 responsive T cells (25,26). In regards to the previous studies, we 
hypothesized that the lack of anti-PD-1-responding tumor-infiltrating CD8+ T cells may be 
one of the causes of HPD. A trend of decreased frequency of CD28+ cells among PD-1+CD8+ 
T cells was shown in HPD. These indicate that an increase in terminally exhausted CD8+ T 
cells may be associated with HPD, and further investigations evaluating the role of CD28− or 
CD39+CD8+ T cells in the development of HPD are required.
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We also examined the change in the frequency and proliferative response of Tregs, which were 
recently claimed to play a major role in HPD (4). Tregs can be subdivided into naïve (Fraction 
I) Tregs, effector (Fraction II) Tregs, and non-suppressive cells (Fraction III) (14). FII Tregs 
mainly exert the well-known suppressive functions of Tregs. In our study, we found an increase 
in Ki-67 expression among FII Tregs regardless of the response to treatment. Moreover, the 
ratio of post-treatment and pre-treatment frequency of Ki-67+ cells among FII Tregs was similar 
among DCB, NHPD, and HPD patients. The results were also similar when Ki-67 expression 
was evaluated among PD-1+ FII Tregs. In contrast, Kamada et al. (4) found that the frequency of 
Ki-67+ cells among tumor-infiltrating FII Tregs was only increased in HPD patients. They utilized 
paired tissue samples from gastric cancer patients obtained before and 4-6 weeks after anti-PD-1 
therapy. In addition, they demonstrated the role of PD-1 in Tregs and found that loss of PD-1 in 
Tregs can lead to tumor growth in a mouse model. The proliferative response or frequency of 
Tregs analyzed using peripheral blood in our study may not properly reflect the status or dynamic 
change in the tumor tissue microenvironment after treatment. Further investigations with paired 
tissue samples may be needed to elucidate the association between Tregs and HPD in humans.
Previous study reported that several clinicopathological factors such as Eastern Cooperative 
Oncology Group performance status, previous lines of treatment, and type of anti-PD-1/PD-L1 
agent were significantly different among DCB, NHPD, and HPD patients. However, no significant 
differences were observed between NHPD and HPD regarding these clinical factors in our study.
The present study has several limitations. First, the number of patients was small, which 
limits the statistical power of this study. In addition, paired peripheral blood samples were 
only available in 61% of patients, and the rest had only baseline peripheral blood samples. 
Second, immune cell analysis was limited to MDSCs and T cells. Applying a more unbiased 
method, such as CyTOF or single-cell RNA sequencing, in a larger population may shed light 
on the novel immune signatures of HPD. Furthermore, paired tissue samples before and after 
ICI treatment, rather than peripheral blood, are needed to better characterize HPD-specific 
changes in the immune microenvironment of tumors.
In conclusion, we propose that a high pre-treatment frequency of CD39+ cells among CD8+ T 
cells might be a characteristic of HPD. Further investigations with a larger cohort are needed 
to validate our results and to better delineate the immune landscape of patients experiencing 
HPD in order to improve the prediction and management of this devastating pattern of 
disease progression.
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